Cargando…
Decitabine/Cedazuridine: First Approval
A fixed dose oral combination (FDC) of decitabine and cedazuridine (Inqovi(®)), is being developed by Astex Pharmaceuticals (a subsidiary of Otsuka Pharmaceuticals) for the treatment of various cancers like myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML), acute myeloid leuka...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708383/ https://www.ncbi.nlm.nih.gov/pubmed/32860582 http://dx.doi.org/10.1007/s40265-020-01389-7 |